Advertisement

Atlas of AIDS pp 316-341 | Cite as

Antiviral Treatments

  • Margaret A. Fischl

Keywords

Human Immunodeficiency Virus Human Immunodeficiency Virus Infection Nucleoside Analogue Antiviral Treatment Zidovudine Group 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Hirsch MS, D’Aquila RT: Therapy for human immunodeficiency virus. N Engl J Med 1993, 328:1686–1695.PubMedCrossRefGoogle Scholar
  2. 2.
    Balzarini J, DeClercq E: Biochemical pharmacology of nucleoside analogs active against HIV. In Broder S, Merigan TC, Bolognesi D (eds.): Textbook of AIDS Medicine. Baltimore: Williams & Wilkins; 1994:751–772.Google Scholar
  3. 3.
    Fischl MA: Combination antiretroviral therapy for HIV infection. Hosp Pract 1994, 29:43–48.Google Scholar
  4. 4.
    Fischl MA, Richman DD, Grieco MH, et al.: The efficacy of azidothymidine [AZT] in the treatment of patients with AIDS and AIDS-related complex: A double-blind, placebo-controlled trial. N Engl J Med 1987, 317:185–191.PubMedCrossRefGoogle Scholar
  5. 5.
    Fischl MA, Parker CB, Pettinelli C, et al.: A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. N Engl J Med 1990, 323:1009–1014.PubMedCrossRefGoogle Scholar
  6. 6.
    Fischl MA, Richman DD, Hansen N, et al.: The safety and efficacy of zidovudine [AZT] in the treatment of subjects with mildly symptomatic human immunodeficiency virus infection: A double-blind, placebo-controlled trial. Ann Intern Med 1990, 112:727–737.PubMedCrossRefGoogle Scholar
  7. 7.
    Volberding PA, Lagakos SW, Koch MA, et al.: Zidovudine in asymptomatic human immunodeficiency virus infection: A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N Engl J Med 1990,322:941–949.PubMedCrossRefGoogle Scholar
  8. 8.
    Vella S, Giuliano M, Pezzotti P, et al.: Survival of zidovudine-treated patients with AIDS compared with that of contemporary untreated patients. JAMA 1992, 267:1232–1236.PubMedCrossRefGoogle Scholar
  9. 9.
    Richman DD: Viral resistance to anti-retroviral therapy. In Broder S, Merigan TC, Bolognesi D (eds.): Textbook of AIDS Medicine. Baltimore: Williams & Wilkins; 1994.Google Scholar
  10. 10.
    McLeod GX, Hammer SM: Nucleoside analogues: Combination therapy. Hosp Prac (of Ed) 1992, 27:14–25.Google Scholar
  11. 11.
    Schinazi RF, Larder BA, Mellors JW: Resistance table: mutations in retroviral genes associated with drug resistance. Int Antiviral News 2000, 8:65–91.Google Scholar
  12. 12.
    Richman DD, Grimes JM, Lagakos SW: Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus. J Acquir Immune Defic Syndr 1990, 3:743–746.PubMedGoogle Scholar
  13. 13.
    Chariot P: Zidovudine myopathy. N Engl J Med 1993, 328:1675.PubMedCrossRefGoogle Scholar
  14. 14.
    Lai KK, Gang DL, Zawacki JK, Cooley TP: Fulminant hepatic failure associated with 2’,3’-dideoxyinosine [ddl]). Ann Intern Med 1991, 115:283–284.PubMedCrossRefGoogle Scholar
  15. 15.
    Kahn JO, Lagakos SW, Richman DD, et al.: A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. N Engl J Med 1992, 327:581–587.PubMedCrossRefGoogle Scholar
  16. 16.
    Spotswood LS, Pavia AT, Peterson D, et al.: Didanosine compared with continuation of zidovudine in HIV-infected patients with signs of clinical deterioration while receiving zidovudine: A randomized, double-blind clinical trial. Ann Intern Med 1994, 120:360–368.CrossRefGoogle Scholar
  17. 17.
    Dolin R, Amato D, Fischl M, et al.: Efficacy of didanosine [ddl] versus zidovudine [ZDV] in patients with no or ≤ 16 weeks of prior ZDV therapy [Abstract WS-B24–1]. Presented at the IX International Conference on AIDS. Berlin, 1993.Google Scholar
  18. 18.
    Fischl MA, Dolin R, Cross A, et al.: Safety and tolerance of didanosine (ddl) in patients with advanced HIV disease. Presented at the IX International Conference on AIDS, Berlin, 1993: P0-B26–2038.Google Scholar
  19. 19.
    Fischl MA, Olson RM, Follansbee SE, et al.: Zalcitabine compared with zidovudine in patients with advanced HIV-1 infection who received previous zidovudine therapy. Ann Intern Med 1993, 118:762–769.PubMedCrossRefGoogle Scholar
  20. 20.
    Abrams DI, Goldman AI, Launer C, et al.: A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection. N Engl J Med 1994, 330:657–662.PubMedCrossRefGoogle Scholar
  21. 21.
    Eron JJ, Benoit SJ, Jemsek J, et al.: Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. N Engl J Med 1995, 333:1662–1669.PubMedCrossRefGoogle Scholar
  22. 22.
    Eron J J, Johnson VA, Merrill DP, et al.: Synergistic inhibition of replication of human immunodeficiency virus type 1, including that of zidovudine-resistant isolate, by zidovudine and 2’,3’-dideoxycytidine in vitro. Antimicrob Agents Chemother 1992, 36:1559–1562.PubMedCrossRefGoogle Scholar
  23. 23.
    Meng TC, Fischl MA, Boota AM, et al.: Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus (HIV) infection. Ann Intern Med 1992, 116:13–20.PubMedCrossRefGoogle Scholar
  24. 24.
    Collier AC, Coombs RW, Fischl MA, et al.: Combination therapy with zidovudine and didanosine compared to zidovudine alone in human immunodeficiency virus type one infection. Ann Intern Med 1993, 119:786–793.Google Scholar
  25. 25.
    Delta Coordinating Committee. Delta: A randomized double-blind controlled trial comparing combinations with zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV infection individuals. Lancet 1996, 348:283–291.CrossRefGoogle Scholar
  26. 26.
    Hammer S, Katzenstein D, Hughes M, et al.: Nucleoside monotherapy (MT) vs combination therapy (CT) in HIV infected adults: A randomized, double-blind, placebo-controlled trial in persons with CD4 cell counts 200–500/mm3 [Abstract LB7]. In the Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 1995.Google Scholar
  27. 27.
    Staszewski S, Morales-Ramirez J, Tashima KT, et al.: Efavirenz plus zidovudine and lamivudine, efavirenz, plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med 1999, 341:1865–1873.PubMedCrossRefGoogle Scholar
  28. 28.
    Fischl M, Greenberg S, Clumeck N, et al.: Ziagen (abacavir, ABC, 1592) combined with 3TC & ZDV is highly effective and durable through 48 weeks in HIV-1 infected antiretroviral-therapy-naive Subjects. 6th Conference on Retroviruses and Opportunistic Infections. Chicago, January-February, 1999 [Abstract 19].Google Scholar
  29. 29.
    Johnston MI, McGowan JJ: Strategies and progress in the development of antiretroviral agents. In DeVita VT, Hellman S, Rosenberg SA (eds.): AIDS: Etiology, Diagnosis, Treatment and Prevention, 3rd ed. Philadelphia: J.B. Lippincott: 1992:357–371.Google Scholar
  30. 30.
    Kohlstaedt LA, Wang J, Friedman JM, et al.: Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 1992,256:1783–1790.PubMedCrossRefGoogle Scholar
  31. 31.
    Montaner JSG, Reiss P, Cooper D, et al.: A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients. JAMA 1998, 279:930–937.PubMedCrossRefGoogle Scholar
  32. 32.
    Staszewski S, Keiser P, Gathe J, et al.: Comparison of antiviral response with abacavir/combivir and indinavir/combivir in therapy-naive adults at 48 weeks (CNA3005). 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 26-September 29,, 1999, San Francisco, CA [Abstract 505].Google Scholar
  33. 33.
    Cameron B, Heath-Chiozzi M, Kravick S, et al.: Prolongation of life and prevention of AIDS in advanced HIV immunodeficiency with ritonavir [Abstract LB6a]. In the Program and abstract of the 3rd Conference on Retroviruses and Opportunistic Infections, Washington, DC, 1996.Google Scholar
  34. 34.
    Gulick RM, Mellors JW, Havlir D, et al.: Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997, 337:734–739.PubMedCrossRefGoogle Scholar
  35. 35.
    Hammer SM, Squires KE, Hughes MD, et al.: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997, 337:725–733.PubMedCrossRefGoogle Scholar
  36. 36.
    Stanley K, Lagakos SW: Biostatistical considerations in the design and analysis of AIDS clinical trials. In Broder S, Merigan TC, Bolognesi D (eds.) Textbook of AIDS Medicine. Baltimore: Williams & Wilkins; 1994:743–750.Google Scholar
  37. 37.
    Graham NM, Piantadosi S, Park LP, et al.: CD4+ lymphocyte response to zidovudine as a predictor of AIDS-free time and survival time. J Acquir Immune Defic Syndr 1993, 6: 1258–1266.PubMedGoogle Scholar
  38. 38.
    O’Brien WA, Hartigan PM, Martin DM, et al.: Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. N Engl J Med 1996, 334:426–431PubMedCrossRefGoogle Scholar
  39. 39.
    Saag MS: Nucleoside analogues: Adverse effects. Hosp Pract 1992, 27:26–36.Google Scholar

Selected Bibliography

  1. Cameron DW, Japour AJ, Xu Y, et al.: Ritonavir and saquinavir combination therapy for the treatment of HIV infection. AIDS 1999,13:213–224.PubMedCrossRefGoogle Scholar
  2. Carpenter CCJ, Cooper DA, Fischl, MA, et al.: Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA panel. JAMA 2000, 283:381–390.PubMedCrossRefGoogle Scholar
  3. Cohen Stuart JWT, Schuurman R, Burger DM, et al.: Randomized trial comparing saquinavir soft gelatin capsules versus indinavir as part of triple therapy (CHEESE study). AIDS 1999, 13:F53-F58.PubMedCrossRefGoogle Scholar
  4. Friedland GH, Pollard R, Griffith B, et al.: Efficacy and safety of delavirdine mesylate with zidovudine and didanosine compared with two-drug combinations of these agents in persons with HIV disease with CD4 counts of 100 to 500 cells/mm3 (ACTG 261). J Acquir Immune Defic Syndr 1999, 21:281–292.PubMedCrossRefGoogle Scholar
  5. Fischl MA, Parker CB, Pettinelli C, et al.: A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. N Engl J Med 1990, 323:1009–1014.PubMedCrossRefGoogle Scholar
  6. Gallant JE, Raines C, Sun E, et al.: A Phase II study of ritonavir-nelfinavir combination therapy. From: 6th Conference on Retroviruses and Opportunistic Infections; January 31-February 4, 1999; Chicago, III. Abstract 393.Google Scholar
  7. Hammer, SM, Squires KE, Hughes MD, et al.: Controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200/mL or less. N Engl J Med. 1997, 337:725–733.PubMedCrossRefGoogle Scholar
  8. Haubrich R, Thompson M, Schooley R, et al.: A phase II safety and efficacy study of amprenavir in combination with zidovudine and lamivudine in HIV-infected patients with limited antiretroviral experience. AIDS 1999, 13:2411–2420.PubMedCrossRefGoogle Scholar
  9. Hirsch MS, Conway B, D’Aquila RT, et al.: Antiretroviral drug resistance testing in HIV infection of adults. JAMA 1998, 279:1984–1991.PubMedCrossRefGoogle Scholar
  10. Hirsch, MS, Steigbigel R, Staszewski S. et al.: A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy. J Infect Dis 1999, 180:659–665.PubMedCrossRefGoogle Scholar
  11. Kahn JO, Lagakos SW, Richman DD, et al.: A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. N Engl J Med 1992, 327:581–587.PubMedCrossRefGoogle Scholar
  12. Moore KH, Shaw S, Laurent AL, et al.: Lamivudine/zidovudine as a combined formulation tablet: bioequivalence compared with lamivudine and zidovudine administered concurrently and the effect of food on absorption. J Clin Pharmacol 1999, 39:593–605.PubMedCrossRefGoogle Scholar
  13. Murphy RL, DeGruttola V, Gulick RM, et al.: Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. AIDS Clinical Trials Group 347 Study Team. J Infect Dis 1999, 179:808–816.PubMedCrossRefGoogle Scholar
  14. Palella FJ, Delaney KM, Moorman AC, et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998, 338:853–860.PubMedCrossRefGoogle Scholar
  15. Parkin NT, Lie YS, Hellmann N, et al.: Phenotypic changes in drug susceptibility associated with failure of human immunodeficiency virus type 1 (HIV-1) triple combination therapy. J Infect Dis 1999, 180:865–870.PubMedCrossRefGoogle Scholar
  16. Saag M, Krowles M, Chang Y, et al.: Durable effect of VIRACEPT (nelfinavir mesylate, NFV) in triple combination therapy. From: 36th Interscience Conference on Antimicrobial Agents and Chemotherapy September 28-October 1st, 1997; Toronto, Ontario. Abstract 1–101.Google Scholar
  17. Safrin S, Grunfeld C: Fat distribution and metabolic changes in patients with HIV infection. AIDS 1999, 13:2493–2505.PubMedCrossRefGoogle Scholar
  18. Tebas P, Patick AK, Kane EM, et al.: Virologie responses o a ritonavir-saquinavir-containing regimen in patients who have previously failed nelfinavir. AIDS 1999, 13:F23-F28.PubMedCrossRefGoogle Scholar
  19. Wanke CA. Epidemiological and clinical aspects of the metabolic complications of HIV infection; The fat redistribution syndrome. AIDS 1999, 13:1287–1293.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • Margaret A. Fischl

There are no affiliations available

Personalised recommendations